BioSpace News Archive

Over the years, the geriatric population around the world has grown continuously.

OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2021 second quarter financial results and certain business developments for 5:00 pm ET on Tuesday, August 3, 2021.

Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced it will release its second quarter financial results on Tuesday, August 10, 2021.

Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its 2021 second quarter operating results on Thursday, August 5, 2021, after market close.

Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced that it will release financial results for the second quarter of 2021 after the close of trading on Tuesday, August 10, 2021.

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory orphan diseases, today announced the closing of a $63 million Series B financing.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2021 on Monday, August 9 at 4:30 p.m. ET / 1:30 p.m. PT.

Pia MacDonald, MPH, Ph.D., an infectious disease epidemiologist at RTI International, a nonprofit research institute, is available for media interviews on the future trajectory of the COVID-19 pandemic, the importance of vaccinations, and the impact of Delta variant and other virus variants on reaching herd immunity moving into the fall.

A new study to be presented this week at Heart Rhythm 2021 and recently published in the American Journal of Cardiology1 shows use of the KardiaMobile 6L device results in a reduction of in-person healthcare utilization.

HUTCHMED Limited and AstraZeneca PLC have initiated a Phase II study of ORPATHYS®, an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, in patients with advanced or metastatic MET amplified gastric cancer or adenocarcinoma of the gastroesophageal junction.